Effective Chemotherapeutic Agents Used in Prostate Cancer Treatment
March 19th, 2008 Posted in prostate chemotherapyProstate cancer is the most common non-cutaneous cancer in the United States. Although most are diagnosed at earlier stages of disease, a significant number of patients will eventually progress to metastatic androgen-independent prostate cancer (AIPC) and will receive chemotherapy.
A recent study at the Stanford University suggests the benefit of chemotherapy in overall survival has been demonstrated in studies utilizing docetaxel. However, duration of response is short and therapeutic options are limited after taxane failure. There is a need for effective chemotherapeutic agents in the second-line setting, either alone or in combination. Some of these regimens may also ultimately translate to the front-line chemotherapeutic setting as an alternative or perhaps in combination with a taxane.
Tags: chemotherapy, docetaxel, epothilones, mitoxantrone, prostate cancer, satraplatin